Soleno Therapeutics stock price target raised to $115 from $108 at Stifel

Soleno Therapeutics (SLNO) has received increased analyst confidence, with Stifel raising its price target to $115 and Piper Sandler reiterating an Overweight rating with a $145 target, driven by strong early indicators for its Prader-Willi syndrome drug, VYKAT XR. A Stifel physician survey revealed robust demand, with 70% of doctors prescribing Vykat and favorable early reimbursement dynamics, leading Stifel to project $2.5 billion in peak sales. Piper Sandler also anticipates sales could surpass $2 billion, significantly above current Wall Street estimates, underscoring the drug's substantial market potential amid strong adoption and promising clinical data as the company prepares for a European launch.

Analysis

Analyst sentiment for Soleno Therapeutics (SLNO) has turned increasingly positive, driven by strong initial launch dynamics for its Prader-Willi syndrome (PWS) drug, VYKAT XR. Stifel raised its price target to $115 from $108, citing a physician survey that revealed robust early demand, with 70% of surveyed doctors already prescribing the medication. The survey also indicated favorable reimbursement trends and unexpected adult utilization, prompting Stifel to model approximately $2.5 billion in peak sales. This optimism is echoed by Piper Sandler, which reiterated a $145 price target and projects potential sales could exceed $2 billion, a figure that significantly surpasses the current Wall Street consensus estimate of $409.1 million for the full year 2025. The bullish outlook is further supported by new clinical data confirming VYKAT XR's efficacy in reducing hyperphagia and its safety for patients with diabetes. With the stock having already surged over 111% in the past year to a $4.28 billion valuation, these revised analyst estimates suggest substantial upside remains if the company can execute on its commercial launch. A European Marketing Authorization Application has also been filed, signaling a key future catalyst with a potential approval anticipated by early 2026.

Key Decisions for Investors

• Investors should recognize the significant gap between bullish analyst sales forecasts, which project over $2 billion in peak sales for VYKAT XR, and the current Wall Street consensus, presenting a potential valuation arbitrage opportunity if early adoption trends continue.
• It is critical to monitor the company's upcoming quarterly reports for initial sales figures and management commentary on reimbursement, as these will be the first hard data points to validate the highly positive physician surveys.
• The European regulatory process for VYKAT XR is a key long-term catalyst to watch, as a potential approval in early 2026 would materially expand the drug's total addressable market.
• Given the stock's 111% appreciation over the past year, investors should weigh the high expectations embedded in the current price against the execution risk associated with a new drug launch, even with strong initial indicators.